Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer
/in International Publications, Pancreatic Cancer /von 2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3709-14Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells
/in International Publications, Pancreatic Cancer /von 2005-07-01 / J. Immunother. 2005 Jul-Aug;28(4):332-42Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells
/in International Publications, Pancreatic Cancer /von 2004-02-01 / J. Gastrointest. Surg. 2004 Feb;8(2):175-81; discussion 181-2In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells
/in International Publications, Pancreatic Cancer /von 2003-03-01 / Int. J. Oncol. 2003 Mar;22(3):651-6[Is total body hyperthermia plus chemotherapy useful in pancreas carcinoma?]
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2002-08-02 / Dtsch. Med. Wochenschr. 2002 Aug;127(31-32):1660The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2002-01-01 / Int J Gastrointest Cancer 2002;32(1):1-6Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines
/in International Publications, Pancreatic Cancer /von 2001-09-01 / Cancer Res. 2001 Sep;61(17):6445-50Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients
/in International Publications, Pancreatic Cancer /von 2000-08-01 / Int J Colorectal Dis 2000 Aug;15(4):197-205Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein
/in International Publications, Pancreatic Cancer /von 2000-07-01 / J. Immunother. 2000 Jul-Aug;23(4):464-72IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de